HarveyMFriedmanMD
Infectious Disease • Philadelphia, PAProfessor of Medicine, University Pennsylvania
Dr. Friedman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce Street
Philadelphia, PA 19104Phone+1 215-662-6932Fax+1 215-662-7899
Education & Training
University of Pennsylvania Health SystemFellowship, Infectious Disease, 1973 - 1975- University of Pennsylvania Health SystemResidency, Internal Medicine, 1973 - 1975
McGill University Faculty of MedicineClass of 1969
Certifications & Licensure
PA State Medical License 1973 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1986
Clinical Trials
- Pilot Study of Text Message Reminders to Improve HIV Medication Adherence in Botswana Start of enrollment: 2008 Jun 01
Publications & Presentations
PubMed
- 3 citationsRapid and accurate detection of herpes simplex virus type 2 using a low-cost electrochemical biosensor.Lucas F de Lima, André L Ferreira, Sita Awasthi, Marcelo D T Torres, Harvey M Friedman
Cell Reports. Physical Science. 2023-09-20 - 31 citationsThrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1.Michael R. Sutherland, Harvey M. Friedman, Edward L.G. Pryzdial
Journal of Thrombosis and Haemostasis. 2007-05-01 - 50 citationsNovel Mechanism of Antibody-Independent Complement Neutralization of Herpes Simplex Virus Type 1Harvey M. Friedman, Liyang Wang, Michael K. Pangburn, John D. Lambris, John M. Lubinski
Journal of Immunology. 2000-10-15
Other
- Vaccinia virus as the smallpox vaccineFriedman HM, Isaacs SN
http://www.uptodate.com/contents/vaccinia-virus-as-the-smallpox-vaccine
UpToDate, Wolters Kluwer Health - 2013-03-18 - The epidemiology, pathogenesis, and clinical manifestations of smallpoxFriedman HM, Isaacs SN
http://www.uptodate.com/contents/the-epidemiology-pathogenesis-and-clinical-manifestations-of-smallp
UpToDate, Wolters Kluwer Health - 2012-03-26 - Vaccinia virus in the research settingFriedman HM, Isaacs SN
http://www.uptodate.com/contents/vaccinia-virus-in-the-research-setting
UpToDate, Wolters Kluwer Health - 2012-03-20
Press Mentions
Race to Develop mRNA Flu Vaccines Will Contend with a Longer Review Than Covid-19August 11th, 2021- After Covid-19, mRNA Technology Aims to Revolutionise the Flu ShotAugust 10th, 2021
- How mRNA Vaccines Could Prevent or Eliminate Infectious Diseases Beyond COVID-19June 15th, 2021
- Join now to see all
Grant Support
- InternationalNational Institute Of Allergy And Infectious Diseases2009–2011
- Blocking Immune Evasion As A Novel HSV Vaccine ApproachNational Heart, Lung, And Blood Institute2008–2010
- Postdoctoral Training Grant In Infectious DiseasesNational Institute Of Allergy And Infectious Diseases2001–2010
- Herpes Simplex Virus FC ReceptorNational Institute Of Allergy And Infectious Diseases1992–2009
- Blocking Immune Evasion As A Nevel HSV Vaccine ApproachNational Heart, Lung, And Blood Institute2007
- Virus &Immune Injury To Vessel Wall CellsNational Heart, Lung, And Blood Institute1991–2006
- Protease Inhibitor-Sparing Regimens For The Initial Treatment Of HIV SubjectsNational Center For Research Resources2005
- Cryopreservation Evaluation In HIV SubjectsNational Center For Research Resources2005
- Comparison Of Lopinavir/Ritonavir PLUS Efavirenz Versus Lopinavir/RitonavirNational Center For Research Resources2005
- Beta-D-2, Dapd, Versus DAPD PLUS MMF In Treatment HIV SubjectsNational Center For Research Resources2005
- ACTG A5116: Simplified Regimens Regimen VS A Nucleoside-Sparing RegimenNational Center For Research Resources2005
- ACTG A5001: Adult AIDS Clinical Trials Group Longitudinal Linked TrialsNational Center For Research Resources2005
- Herpes Simplex Virus Immune Evasion In HIV SubjectsNational Institute Of Dental &Craniofacial Research2001–2005
- Lopinavir/Ritonavir PLUS Efavirenz Versus Lopinavir/RitNational Center For Research Resources2004
- HIV Infected Subjects WHO Have 200 HIV-1 RNA Copies/MlNational Center For Research Resources2004
- Beta-D-2,6-Diaminopurine Dioxolane Versus DAPD PLUS Mycophenolate MofetilNational Center For Research Resources2004
- Adult AIDS Clinical Trials Group Longitudinal Linked Randomized TrialsNational Center For Research Resources2004
- 3 Protease Inhibitor-Sparing Regimens For The Initial Treatment Of HIV InfectionNational Center For Research Resources2004
- Sb-265805 Compared With Cefuroxime Axetil In Acute SinusNational Center For Research Resources2000–2002
- Core--Clinical FacilityNational Institute Of Allergy And Infectious Diseases1999–2002
- ACTG 892: Effect Of Highly Active Antiretroviral Therapy On Lean BodyNational Center For Research Resources1999–2002
- ACTG 383:Subjects W/ Hepatitis C Virus &Human Immunodeficiency VirusNational Center For Research Resources1999–2002
- HSV 007--Skbs HSV Vaccine To Prevent Genital Herpes In Healthy SubjectsNational Center For Research Resources1998–2002
- ACTG 360-- Prospective Study Of HIV Wrt CMV Burden Endorgan DiseaseNational Center For Research Resources1998–2002
- Hsv107--Herpes Simplex Vaccine (GD2T) In HSV + Or - Consorts With Genital HerpesNational Center For Research Resources1997–2002
- AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1996–2002
- HSV 16--Herpes Simplex Candidate Vaccine With MPL In HSV PTS W/O Genital HerpesNational Center For Research Resources1997–2000
- Virus And Immune Injury To Vessel Wall CellsNational Heart, Lung, And Blood Institute1987–2000
- Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
- Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
- Outreach AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
- Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
- Neurology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
- Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
- HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
- Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1997–1999
- Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
- Herpes Simplex Virus FC ReceptorNational Institute Of Allergy And Infectious Diseases1997
- HSV 007--Skbs HSV Vaccine To Prevent Genital Herpes In Healthy SubjectsaNational Center For Research Resources1997
- Actg229--Ro31 8959 PLUS Zidovudine VS Zidovudine PLUS DDCNational Center For Research Resources1997
- ACTG 244--Condon 215 Mutation In Zvd Monotherapy/Maintenance TherpyNational Center For Research Resources1997
- ZDV VS ZDV + Ddl VS ZDV + Ddl + NVP In Asymptomatic HIV PatientsNational Center For Research Resources1996
- Actg229--Ro31-8959 PLUS Zidovudine VS Zidovudine PLUS ZalcitabineNational Center For Research Resources1996
- AIDS Clinical TrialNational Institute Of Allergy And Infectious Diseases1994–1995
- AIDS Clinical Trial UnitNational Institute Of Allergy And Infectious Diseases1992–1993
- Steroid Regulation Of HSV 1 Glycoprotein C ExpressionFogarty International Center1986
- Virus And Immune Injury To Vessel Wall CellsNational Heart, Lung, And Blood Institute1985–1986
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
